The Business

Welcome to IDEC Pharmaceuticals’ newly redesigned website.

The poet Carl Sandburg once said, “Nothing happens unless first a dream.” As we approach the end of 2001, IDEC is eager to fulfill, pending FDA approval, a long-held dream commercializing a “hot” monoclonal antibody. In the late 1980s and early 1990s the dream of developing and commercializing a radioactive antibody for the treatment of cancers was much talked about but never realized.

In the late 1980s, IDEC initiated clinical trials using iodine-131, a radioisotope, linked to an antibody for the treatment of non-Hodgkin’s lymphoma (NHL). However, due to certain requirements at the time for hospitalization of patients receiving radioactive iodine and other complications of utilizing this particular radioisotope, IDEC deemed the trial too impractical and too costly to pursue. continue